LPS also seems to promote IR, dyslipidemia, hepatic inflammation, and fibrosis through activation of Toll-like receptor 4 (TLR4) and LPS binding protein in the gut, liver, and adipose tissue (45, 46). Here, TLR4 is linked to metabolic syndrome.